Year: 2019

Stock Analysts

Is Packaging Corporation (PKG) a Great Stock for Value Investors?

January 4, 2019 0

Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process […]

Technicals

Why Federated Investors (FII) Could Beat Earnings Estimates Again

January 4, 2019 0

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Federated Investors (FII), which belongs to the Zacks Financial – Investment Management industry, could be a great candidate to consider. This one of the nation’s largest managers of money market funds has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports […]

Technicals

Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?

January 4, 2019 0

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Thermo Fisher Scientific (TMO), which belongs to the Zacks Medical – Instruments industry, could be a great candidate to consider. When looking at the last two reports, this maker of scientific instrument and laboratory supplies has recorded a strong streak of surpassing earnings estimates […]

Technicals

Why Allergan (AGN) Could Beat Earnings Estimates Again

January 4, 2019 0

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering Allergan (AGN), which belongs to the Zacks Medical – Generic Drugs industry. This Botox maker has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports […]

Technicals

Why Landstar (LSTR) Could Beat Earnings Estimates Again

January 4, 2019 0

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Landstar System (LSTR). This company, which is in the Zacks Transportation – Truck industry, shows potential for another earnings beat. This freight shipper and warehouser has an established record of topping earnings estimates, especially when looking at the previous two reports. […]

Technicals

Why Lear (LEA) Could Beat Earnings Estimates Again

January 4, 2019 0

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Lear (LEA). This company, which is in the Zacks Automotive – Original Equipment industry, shows potential for another earnings beat. This automotive seating and electrical distribution systems company has an established record of topping earnings estimates, especially when looking at the previous two reports. […]

Stock Analysts

Vertex Joins Forces With Arbor to Build Gene-Editing Therapies

January 4, 2019 0

Vertex Pharmaceuticals Incorporated VRTX announced that it has entered into a strategic research collaboration deal with privately held, Massachusetts-based Arbor Biotechnologies to discover novel proteins that the former may use in developing gene-editing therapies to treat five serious diseases including cystic fibrosis (CF). Following this deal, Vertex is looking to leverage Arbor's protein biodiscovery platform based on machine learning, genome sequencing, gene synthesis and high-throughput screening. […]

Stock Analysts

Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate

January 4, 2019 0

The pharma sector was relatively lying low this week with some news grabbing attention only towards the end. Top stories this week were Bristol-Myers’ BMY offer to buy cancer giant Celgene Corporation CELG in a cash and stock deal worth $74 billion and Merck’s MRK decision to exercise the option to in-license a NASH candidate from partner NGM Biopharmaceuticals. Recap of the Week’s Most Important Headlines Bristol-Myers to Acquire Celgene for $74B : Bristol-Myers began the year announcing one of the largest merger deals in the biotech/pharma sector. […]

Stock Analysts

Abercrombie (ANF) Stock to Remain a Lucrative Pick in 2019

January 4, 2019 0

Abercrombie & Fitch Company ANF is one retail stock that has displayed strength in fiscal 2018, thanks to its impressive growth strategies that include planned capital investments and cost-saving efforts as well as loyalty and marketing programs. Further, robust Hollister and direct-to-consumer (DTC) business performances are the key catalysts in Abercrombie’s growth story. These efforts have not only supported the company’s robust surprise trend but also helped maintain stock momentum all through the past year. […]